Lv1
36 积分 2024-12-03 加入
HTA137 The Changing Landscape of Health Technology Assessment (HTA) in the Asia-Pacific (APAC) Region: Advances, Challenges, and Future Goals
1小时前
求助中
Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
25天前
已完结
CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA
1个月前
已完结
皖公网安备34019202002308
